HLS Therapeutics Inc Stock Toronto S.E.
Stocks
AM
CA05328X1015
Pharmaceuticals
OTC Markets Traded
| Market Cap | 94.93M 82.71M 76.25M 71.72M 134M 8.95B 135M 907M 352M 4.41B 356M 349M 15.28B | P/E 2026 * |
-15.2x | P/E 2027 * | -101x |
|---|---|---|---|---|---|
| Enterprise Value | 94.93M 82.71M 76.25M 71.72M 134M 8.95B 135M 907M 352M 4.41B 356M 349M 15.28B | EV / Sales 2026 * |
1.64x | EV / Sales 2027 * | 1.48x |
| Free-Float |
99.48% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HLS Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 58 | 01/05/2023 |
John Hanna
DFI | Director of Finance/CFO | 61 | 26/01/2024 |
Jason Gross
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/06/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Rodney Hill
BRD | Director/Board Member | 58 | 12/03/2018 |
John Welborn
CHM | Chairman | 48 | 22/06/2023 |
Norma Beauchamp
BRD | Director/Board Member | 65 | 01/01/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -0.41% | - | - | 94.93M | |
| +0.15% | -4.64% | +2.98% | +84.79% | 87.88B | |
| -1.99% | +0.28% | +34.08% | +143.04% | 51.94B | |
| -1.78% | +2.60% | -14.81% | +224.71% | 22.71B | |
| -1.24% | -2.03% | -9.60% | -26.78% | 7.96B | |
| +2.31% | -2.71% | -31.28% | -32.89% | 7.35B | |
| -2.73% | -2.50% | -10.78% | -36.88% | 6.52B | |
| -1.38% | -4.99% | +13.44% | +16.30% | 6.21B | |
| +1.32% | -0.88% | -2.26% | +18.26% | 5.15B | |
| +1.47% | +2.11% | -5.48% | -13.58% | 3.56B | |
| Average | -0.86% | -0.83% | -2.64% | +41.88% | 22.14B | |
| Weighted average by Cap. | -2.43% | +0.60% | +6.88% | +97.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 58.03M 50.56M 46.61M 43.84M 82.02M 5.47B 82.59M 555M 215M 2.7B 218M 213M 9.34B | 64.31M 56.04M 51.66M 48.59M 90.9M 6.06B 91.54M 615M 239M 2.99B 241M 236M 10.35B |
| Net income | -6.26M -5.46M -5.03M -4.73M -8.85M -590M -8.92M -59.86M -23.25M -291M -23.51M -23.01M -1.01B | -1.05M -915K -843K -793K -1.48M -98.96M -1.49M -10.03M -3.9M -48.77M -3.94M -3.86M -169M |
| Net Debt | - | - |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
